BioXcel Therapeutics, Inc.

BTAI - CIK 0001720893

Market cap-

Rank-

SEC filings656

BTAI income statement (annual)

The table below shows BioXcel Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$642.00K	$2.27M	$1.38M	$375.00K	-	-
Cost of revenue	$164.00K	$2.14M	$1.26M	$20.00K	-	-
Gross profit	-	-	-	-	-	-
R&D	$30.25M	$30.43M	$84.33M	$91.24M	$52.71M	$57.99M
SG&A

BTAI annual revenue (10-K history)

BioXcel Therapeutics, Inc. reported annual revenue of $642.00K for fiscal year 2025. That is down 71.7% from $2.27M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.